Grace TherapeuticsGRCE
13F holders, Q3 2024 (September 30)1holders
$3.00avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Grace Therapeutics Inc. (GRCE) in their 13F filings. The largest holder was ADAR1 Capital Management, LLC ($2.9M).
- Company
- Grace Therapeutics Inc.
- Filed as
- ACASTI PHARMA INC (Q3 2024)
- CUSIP
- 00439U104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2.9M |
| Exits | 0 | $0 |
Ownership 1 holders
| ADAR1 Capital Management, LLC | 0.48% | New | 959,571 | $2.9M |
"% of holder's portfolio" is GRCE's weight in each manager's 13F, not the share of Grace Therapeutics Inc. the manager owns.